A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
NCT ID: NCT06431607
Last Updated: 2025-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
840 participants
INTERVENTIONAL
2024-05-23
2025-06-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
NCT05823974
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
NCT07121192
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
NCT07204964
A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
NCT05446740
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
NCT06382311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Flu mRNA_YA_Group 1
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 1
1 dose of Flu mRNA Formulation 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Flu mRNA_YA_Group 2
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 2
1 dose of Flu mRNA Formulation 2 is administered intramuscularly in the non-dominant upper deltoid to YA at Day 1.
Flu mRNA_YA_Group 3
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 3
1 dose of Flu mRNA Formulation 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Flu mRNA_YA_Group 4
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 4
1 dose of Flu mRNA Formulation 4 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
YA_Active Comparator Group 1
Eligible participants receive 1 dose of an active comparator at Day 1 intramuscularly.
Active Comparator 1
1 dose of active comparator 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Flu mRNA_OA_Group 1
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 5
1 dose of Flu mRNA Formulation 5 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Flu mRNA_OA_Group 2
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 6
1 dose of Flu mRNA Formulation 6 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Flu mRNA_OA_Group 3
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 7
1 dose of Flu mRNA Formulation 7 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Flu mRNA_OA_Group 4
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 8
1 dose of Flu mRNA Formulation 8 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
OA_Active Comparator Group 2
Eligible participants receive 1 dose of an active comparator at Day 1 intramuscularly.
Active Comparator 2
1 dose of active comparator 2 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Flu mRNA_YA_Group 5
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 9
1 dose of Flu mRNA Formulation 9 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
YA_Active Comparator Group 3
Eligible participants receive 1 dose of an active comparator at Day 1 intramuscularly.
Active Comparator 3
1 dose of active comparator 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Flu mRNA_OA_Group 5
Eligible participants receive 1 dose of study intervention at Day 1 intramuscularly.
Flu Seasonal mRNA Formulation 10
1 dose of Flu mRNA Formulation 10 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
OA_Active Comparator Group 4
Eligible participants receive 1 dose of an active comparator at Day 1 intramuscularly.
Active Comparator 4
1 dose of active comparator 4 is administered intramuscularly in the non-dominant upper deltoid to OA at Day1.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flu Seasonal mRNA Formulation 1
1 dose of Flu mRNA Formulation 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Flu Seasonal mRNA Formulation 2
1 dose of Flu mRNA Formulation 2 is administered intramuscularly in the non-dominant upper deltoid to YA at Day 1.
Flu Seasonal mRNA Formulation 3
1 dose of Flu mRNA Formulation 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Flu Seasonal mRNA Formulation 4
1 dose of Flu mRNA Formulation 4 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Flu Seasonal mRNA Formulation 5
1 dose of Flu mRNA Formulation 5 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Flu Seasonal mRNA Formulation 6
1 dose of Flu mRNA Formulation 6 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Flu Seasonal mRNA Formulation 7
1 dose of Flu mRNA Formulation 7 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Flu Seasonal mRNA Formulation 8
1 dose of Flu mRNA Formulation 8 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Active Comparator 1
1 dose of active comparator 1 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Active Comparator 2
1 dose of active comparator 2 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Flu Seasonal mRNA Formulation 9
1 dose of Flu mRNA Formulation 9 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Flu Seasonal mRNA Formulation 10
1 dose of Flu mRNA Formulation 10 is administered intramuscularly in the non-dominant upper deltoid to OA participants at Day 1.
Active Comparator 3
1 dose of active comparator 3 is administered intramuscularly in the non-dominant upper deltoid to YA participants at Day 1.
Active Comparator 4
1 dose of active comparator 4 is administered intramuscularly in the non-dominant upper deltoid to OA at Day1.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy participants or medically stable patients as established by medical history and clinical examination. Participants with chronic medical conditions with or without specific treatment (e.g., chronic metabolic, cardiac, pulmonary, renal, hepatic, neurologic, and hematologic diseases) are allowed to participate in this study if considered by the investigator as medically stable. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrolment.
3. Body mass index (BMI) \>=18 Kilograms per meter square (kg/m²) and less than or equal to (\<=) 35kg/m2.
4. Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits), independently or with the assistance of a caregiver.
5. Written informed consent obtained from the participant prior to performance of any study-specific procedure.
6. Female participants of non-childbearing potential may be enrolled in the clinical study.
7. Female participants of childbearing potential may be enrolled in the clinical study, if the participant:
* Has practiced adequate contraception for 1 month prior to the study intervention administration, and
* Has a negative pregnancy test within 24 hours prior to the study intervention administration, and
* Has agreed to continue adequate contraception for at least 1 month after study intervention administration.
Exclusion Criteria
2. Current or past malignancy, unless completely resolved without sequelae for greater than (\>) 5 years before the study intervention administration (excluding effectively treated basal cell skin cancer).
3. Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing required). HIV-infected individuals may be enrolled if they have been stable on antiretroviral therapy for the past 6 consecutive months, i.e., their treatment has not been modified, their cluster of differentiation 4 (CD4) cell count is \>= 200/ cubic millimeter (mm³) and their viral load has been undetectable (i.e., HIV-RNA lesser than (\<) 50 copies/milliliter \[mL\]) (based on medical records, no laboratory testing required).
4. Participants with a history of, or current suspicion of myocarditis, pericarditis, or idiopathic cardiomyopathy (including a history of myocarditis or pericarditis following vaccination with an mRNA COVID-19 vaccine), or presence of any medical condition that increases risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, hypersensitivity myocarditis, eosinophilic granulomatosis with polyangiitis and persistent myocardial infection will be excluded from the study.
5. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention (including polyethylene glycol, egg proteins and aminoglycoside antibiotics).
6. Hypersensitivity to latex.
7. Recurrent history or uncontrolled neurological disorders or seizures, including Guillain-Barré syndrome and Bell's palsy, with the exception of febrile seizures during childhood.
8. Any history of dementia or any medical condition that moderately or severely impairs cognition.
9. Any condition that in the judgment of the investigator would make intramuscular injection unsafe.
10. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.
11. Administration of an influenza vaccine within 180 days before enrollment or planned administration prior to Visit 2 (Day 29) after the study intervention administration.
12. Previous vaccination with a mRNA influenza vaccine.
13. Administration of a vaccine not foreseen by the study protocol in the period starting 30 days (Day -30) before the study intervention administration, or planned administration within 28 days (Visit 2 \[Day 29\]) after the study intervention administration\*.
* If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced, provided it is used according to the local governmental recommendations and sponsor is notified.
14. Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study intervention during the period beginning 30 days before the study intervention administration, or their planned use during the study period.
15. Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention administration or planned administration during the study period.
16. Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.
* Up to 3 months prior to the study intervention administration:
For corticosteroids, this will mean prednisone equivalent \>=20 mg/day. Inhaled, intraarticular and topical steroids are allowed.
* Up to 3 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication.
17. Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device).
18. Pregnant or lactating female participant.
19. Bedridden participants.
20. Female participant planning to become pregnant or planning to discontinue contraceptive precautions within the 1-month post-dosing period.
21. History of chronic alcohol consumption and/or drug abuse in the past 5 years as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
22. Any study personnel or their immediate dependents, family, or household members.
23. Participants with extensive tattoos covering deltoid region on both arms that would preclude the assessment of local reactogenicity.
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Hialeah, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Valparaiso, Indiana, United States
GSK Investigational Site
El Dorado, Kansas, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Newton, Kansas, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Greensboro, North Carolina, United States
GSK Investigational Site
Knoxville, Tennessee, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
Tomball, Texas, United States
GSK Investigational Site
Newport News, Virginia, United States
GSK Investigational Site
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
222853
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.